Log in
Enquire now
‌

US Patent 11420956 Ureas having Androgen Receptor degradation activity and uses thereof

Patent 11420956 was granted and assigned to Accutar Biotech on August, 2022 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent
0

Patent attributes

Patent Applicant
Accutar Biotech
Accutar Biotech
0
Current Assignee
Accutar Biotech
Accutar Biotech
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
114209560
Patent Inventor Names
Wei He0
Ke Liu0
Yimin Qian0
Jie Fan0
Date of Patent
August 23, 2022
0
Patent Application Number
170286120
Date Filed
September 22, 2020
0
Patent Citations Received
‌
US Patent 12122763 Substituted piperidines for androgen receptor degradation
0
‌
US Patent 11883393 Compounds and methods for the targeted degradation of androgen receptor
0
0
Patent Primary Examiner
‌
Heidi Reese
0

The present disclosure relates to novel compounds, pharmaceutical compositions containing such compounds, and their use in prevention and treatment of cancer and related diseases and conditions. In some embodiments, the compounds disclosed herein exhibit androgen receptor degradation activity.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 11420956 Ureas having Androgen Receptor degradation activity and uses thereof

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.